Astrazeneca Lp Drug Patent Portfolio

Astrazeneca Lp's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

AstraZeneca PLC shares (US6549022043): Can their leadership in oncology lead to new opportunities?

13 Apr, 2026

AstraZeneca and Sun Resolve Patent Disputes Concerning Three Diabetes Medications - Bloomberg Law News

09 Apr, 2026

Guggenheim Increases AstraZeneca Price Forecast Prior to First Quarter Earnings Report - 24/7 Wall St.

30 Mar, 2026

AstraZeneca plc's shares are under examination due to challenges in its oncology pipeline and delays in regulatory approvals.

26 Mar, 2026